Exclusive Summary

• • Potent G-protein biased agonist of hGLP1R.
• • Robust effects in glucose tolerance tests in mice and Superior in vivo efficacy in DIO mice & obese monkey models vs. Orforglipron.
• • Micellar formulation developed in-house to improve the drug bioavailability.
• • No requirement for spray-dried dispersions (used for orforglipron) may provide advantage in manufacturing costs.
• • Robust safety package, including 13-week studies in monkeys and mouse EFD studies.
• • Solid patents layout.

Asset Materials

Contact Us for Full Materials